Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading higher and trending. The company on Tuesday announced a reduction in personnel and infrastructure aimed at extending its cash runway.
What Happened: In connection with the company’s previously announced streamlined operating strategy, Recursion Pharmaceuticals announced a workforce reduction of approximately 20%, extending its cash runway into the fourth quarter of 2027.
The Nvidia-backed biotech company now expects its cash burn to be below $450 million in 2025 and under $390 million in 2026. As of March 31, Recursion had $509 million in cash, cash equivalents and restricted cash. The company expects to report a cash position above $500 million at the end of the current quarter.
Recursion isn’t expected to report quarterly financial results again until early August. Analysts currently expect the company to report a loss of 47 cents per share and revenue of $17.28 million, according to estimates from Benzinga Pro.
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Recursion’s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
RXRX Price Action: Recursion shares were up 6.1% at $5.70 at the time of publication Tuesday, according to Benzinga Pro.
Read Next:
Photo: Shutterstock.